Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy

Abstract From October 2017 to June 2022, we retrospectively report outcomes of R/R DLBCL patients with failure of CAR-T therapy, then receiving allo-HSCT. Among 10 patients, 5 were males and 5 females, with a median age of 43.5 (27–52) years. All patients were diagnosed refractory/relapsed diffuse l...

Full description

Bibliographic Details
Published in:	Experimental Hematology & Oncology
Main Authors:	Mengya Cong, Sicheng Ai, Liqing Kang, Mao Jin, Ying Zhu, Caixia Li, Zhengming Jin, Lei Yu, Depei Wu, Haiwen Huang
Format:	Article
Language:	English
Published:	BMC 2024-01-01
Subjects:	R/R DLBCL CAR-T Allogeneic hematopoietic stem cell transplantation Retrospective analysis
Online Access:	https://doi.org/10.1186/s40164-024-00473-y

Similar Items

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
by: Guido Lancman, et al.
Published: (2018-01-01)

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example
by: Gloria Iacoboni, et al.
Published: (2024-12-01)

Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature
by: N G GABEEVA, et al.
Published: (2018-07-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
by: Madiha Iqbal, et al.
Published: (2022-01-01)

Recent Advances in Allogeneic CAR-T Cells
by: Dong Wook Kim, et al.
Published: (2020-02-01)

Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
by: Jiajie He, et al.
Published: (2023-11-01)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
by: Wenping Zhou, et al.
Published: (2023-09-01)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
by: Hongzhi Geng, et al.
Published: (2023-08-01)

Changes in the bacterial profile and diversity of the gut microbiota in allogeneic hematopoietic stem cell transplant recipients
by: Claudia González-Rico, et al.
Published: (2025-12-01)

Editorial: Immunology of allogeneic hematopoietic stem cell transplantation
by: Carmelo Gurnari, et al.
Published: (2025-02-01)

Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
by: Linyan Tian, et al.
Published: (2023-01-01)

Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients
by: Wenyu Zhao, et al.
Published: (2024-02-01)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
by: Samuel C. F. Couto, et al.
Published: (2023-08-01)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
by: Kenneth J. Caldwell, et al.
Published: (2021-01-01)

Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
by: Marie-Julia Ziliotis, et al.
Published: (2024-04-01)

Quimerismo molecular en el trasplante alogénico de células hematopoyéticas: Resultados preliminares Molecular chimerism in the allogeneic transplantation of hematopoietic cells: Preliminary results
Published: (2005-12-01)

Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
by: Fatemeh Riasi, et al.
Published: (2023-12-01)

Meta-analysis on the efficacy of allogeneic hematopoietic stem cell transplantation to treat malignant lymphoma
by: Zhao Jin, et al.
Published: (2024-05-01)

Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill
by: Paschalis Evangelidis, et al.
Published: (2024-05-01)

Hepatic complications of allogeneic hematopoietic cell transplantation
by: Ramazan Idilman, et al.
Published: (2008-09-01)

The Effect of the COVID-19 Pandemic on Unrelated Allogeneic Hematopoietic Donor Collections and Safety
by: Gaganvir Parmar, et al.
Published: (2023-03-01)

Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method
by: Na Sun, et al.
Published: (2024-12-01)

Monoclonal antibodies binding to different epitopes of CD20 differentially sensitize DLBCL to different classes of chemotherapy
by: Brian Lee, et al.
Published: (2023-08-01)

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer
by: Nuri Karadurmus, et al.
Published: (2018-04-01)

The benefit of exercise in patients who undergo allogeneic hematopoietic stem cell transplantation
by: Shinichiro Morishita, et al.
Published: (2019-01-01)

Tubular basement membrane deposits after allogeneic hematopoietic stem cell transplantation
by: Wenyan Zhou, et al.
Published: (2023-08-01)

Physiological problems in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation
by: Sevgisun Kapucu, et al.
Published: (2014-01-01)

Monitoring of chimerism after allogeneic hematopoietic stem cell transplantation
by: D. S. Dubnyak, et al.
Published: (2022-12-01)

Longitudinal analysis at three oral sites links oral microbiota to clinical outcomes in allogeneic hematopoietic stem-cell transplant
by: Vitor Heidrich, et al.
Published: (2023-12-01)

Clinical Value of miR-3151 Overexpression in Synergistic Interaction with BAALC Host Gene in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
by: AI Shakirova, et al.
Published: (2019-05-01)

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
by: Majid Teremmahi Ardestani, et al.
Published: (2018-08-01)

A Comparison of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia
by: Farnaz Khatami, et al.
Published: (2009-01-01)

A Comparison of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia
by: Ardeshir Ghavamzadeh, et al.
Published: (2009-03-01)

Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
by: Mira Romany Massoud, et al.

Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation
by: Wen-Rong Huang, et al.
Published: (2018-01-01)

Analysis of risk factors for relapse after allogeneic hematopoietic stem cell transplantation in acute leukemia
by: Jiawen Wang, et al.
Published: (2025-12-01)

LYMPHOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION. THE CASE OF SECONDARY HODGKIN’S LYMPHOMA, DIFFERENTIAL DIAGNOSIS WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
by: Yu. V. Skvortsova, et al.
Published: (2017-06-01)

Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes
by: Reena V. Jayani, et al.
Published: (2021-03-01)

Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation
by: Nataliya Prokopenko Buxbaum, et al.
Published: (2020-08-01)